DR Congo Expands Ervebo Ebola Vaccination to Ituri Province Amid Record Outbreak
Democratic Republic of the Congo health authorities and international partners have expanded Ebola vaccination into Ituri Province through the launch of the BRAVO study in Bunia.
In Brief
- •Democratic Republic of the Congo health authorities and international partners have expanded Ebola vaccination into Ituri Province through the launch of the BRAVO study in Bunia.
- •Over 3,700 high-risk individuals have been vaccinated using the Ervebo vaccine across DRC, primarily in Tshopo and Bas-Uele provinces, according to government updates.
- •The BRAVO study plans to vaccinate around 20,000 frontline workers across Ituri and North Kivu to test Ervebo's effectiveness against the Bundibugyo virus strain.
- •The ongoing epidemic, declared in May, is the largest Ebola outbreak in DRC history, recording 7,541 confirmed cases and 3,639 deaths.
Why It Matters
This expansion represents a critical scientific and public health measure in combatting the country's worst Ebola outbreak on record. Because the Ervebo vaccine was developed specifically to target the Zaire strain rather than the Bundibugyo strain driving the current outbreak, the study provides a vital opportunity to generate clinical data on cross-protection while offering preventive coverage to frontline health staff. Successfully managing the epidemic in eastern DRC is crucial for regional stability and health security across Central and East Africa, particularly given the high fatality rate of nearly 50 percent and the high mobility of populations across neighboring provinces.
Key Details
- Confirmed Cases
- 7,541
- Total Reported Deaths
- 3,639
- Case Fatality Rate
- 48.3%
- Vaccinated Individuals
- 3,771
- Initial Approved Vaccine Doses
- 70,000
- Target Frontline Workers in BRAVO Study
- 20,000
Context & Background
The current outbreak, which began in May, has surpassed all previous Ebola epidemics recorded within the Democratic Republic of the Congo. Globally, it stands as the second-largest Ebola epidemic in history, behind only the 2014-2016 outbreak in West Africa.
What To Watch
The execution of the three-month vaccination phase of the 9-to-12-month BRAVO study in Ituri and North Kivu, alongside the implementation of a planned randomized ring-vaccination Phase 3 trial.
Original Reporting & Sources
VNews is an independent briefing product. Original reporting remains credited to the following publishers:
This brief was synthesized automatically using attributed third-party reporting. VNews is a digital news publication produced under the VContent Group brand and operated by Francis Vincent Sunday in Ghana, independent from the publishers cited above. Read our AI Transparency Policy and Editorial & Corrections Policy.